Daiichi Sankyo Company Limited
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 rec… Read more
Daiichi Sankyo Company Limited (DSKYF) - Net Assets
Latest net assets as of December 2025: $1.71 Trillion USD
Based on the latest financial reports, Daiichi Sankyo Company Limited (DSKYF) has net assets worth $1.71 Trillion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.83 Trillion) and total liabilities ($2.11 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.71 Trillion |
| % of Total Assets | 44.76% |
| Annual Growth Rate | 4.13% |
| 5-Year Change | 27.01% |
| 10-Year Change | 31.56% |
| Growth Volatility | 17.89 |
Daiichi Sankyo Company Limited - Net Assets Trend (2003–2025)
This chart illustrates how Daiichi Sankyo Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Daiichi Sankyo Company Limited (2003–2025)
The table below shows the annual net assets of Daiichi Sankyo Company Limited from 2003 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $1.62 Trillion | -3.86% |
| 2024-03-31 | $1.69 Trillion | +16.31% |
| 2023-03-31 | $1.45 Trillion | +7.02% |
| 2022-03-31 | $1.36 Trillion | +6.13% |
| 2021-03-31 | $1.28 Trillion | -2.73% |
| 2020-03-31 | $1.31 Trillion | +5.15% |
| 2019-03-31 | $1.25 Trillion | +10.30% |
| 2018-03-31 | $1.13 Trillion | -3.28% |
| 2017-03-31 | $1.17 Trillion | -5.07% |
| 2016-03-31 | $1.23 Trillion | -5.59% |
| 2015-03-31 | $1.31 Trillion | +29.73% |
| 2014-03-31 | $1.01 Trillion | +7.36% |
| 2013-03-31 | $938.48 Billion | +10.24% |
| 2012-03-31 | $851.31 Billion | -4.10% |
| 2011-03-31 | $887.70 Billion | -0.20% |
| 2010-03-31 | $889.51 Billion | +0.10% |
| 2009-03-31 | $888.62 Billion | -28.60% |
| 2008-03-31 | $1.24 Trillion | -2.17% |
| 2007-03-31 | $1.27 Trillion | +1.84% |
| 2006-03-31 | $1.25 Trillion | +72.05% |
| 2005-03-31 | $726.02 Billion | +5.00% |
| 2004-03-31 | $691.44 Billion | +3.65% |
| 2003-03-31 | $667.09 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Daiichi Sankyo Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 145704400000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.46 Trillion | 89.75% |
| Common Stock | $50.00 Billion | 3.08% |
| Other Components | $116.37 Billion | 7.17% |
| Total Equity | $1.62 Trillion | 100.00% |
Daiichi Sankyo Company Limited Competitors by Market Cap
The table below lists competitors of Daiichi Sankyo Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Constellation Software Inc
PINK:CNSWF
|
$37.07 Billion |
|
PetroChina Company Limited
F:PC6
|
$37.08 Billion |
|
The Kroger Co.
SA:K1RC34
|
$37.13 Billion |
|
Kinross Gold Corporation
NYSE:KGC
|
$37.19 Billion |
|
DNB Bank ASA
PINK:DNBBY
|
$37.00 Billion |
|
Cenovus Energy Inc
NYSE:CVE
|
$36.85 Billion |
|
EQT Corporation
NYSE:EQT
|
$36.63 Billion |
|
Dai-ichi Life Holdings Inc
PINK:DLICY
|
$36.61 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daiichi Sankyo Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,688,173,000,000 to 1,623,416,000,000, a change of -64,757,000,000 (-3.8%).
- Net income of 295,756,000,000 contributed positively to equity growth.
- Dividend payments of 114,317,000,000 reduced retained earnings.
- Share repurchases of 246,066,000,000 reduced equity.
- Other comprehensive income decreased equity by 283,998,000,000.
- Other factors increased equity by 283,868,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $295.76 Billion | +18.22% |
| Dividends Paid | $114.32 Billion | -7.04% |
| Share Repurchases | $246.07 Billion | -15.16% |
| Other Comprehensive Income | $-284.00 Billion | -17.49% |
| Other Changes | $283.87 Billion | +17.49% |
| Total Change | $- | -3.84% |
Book Value vs Market Value Analysis
This analysis compares Daiichi Sankyo Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-03-31 | $446.86 | $23.63 | x |
| 2001-03-31 | $489.15 | $23.63 | x |
| 2002-03-31 | $480.60 | $23.63 | x |
| 2003-03-31 | $492.08 | $23.63 | x |
| 2004-03-31 | $516.64 | $23.63 | x |
| 2005-03-31 | $553.00 | $23.63 | x |
| 2006-03-31 | $561.99 | $23.63 | x |
| 2007-03-31 | $580.09 | $23.63 | x |
| 2008-03-31 | $574.74 | $23.63 | x |
| 2009-03-31 | $407.25 | $23.63 | x |
| 2010-03-31 | $406.53 | $23.63 | x |
| 2011-03-31 | $403.33 | $23.63 | x |
| 2012-03-31 | $390.01 | $23.63 | x |
| 2013-03-31 | $428.62 | $23.63 | x |
| 2014-03-31 | $463.13 | $23.63 | x |
| 2015-03-31 | $616.20 | $23.63 | x |
| 2016-03-31 | $594.18 | $23.63 | x |
| 2017-03-31 | $582.39 | $23.63 | x |
| 2018-03-31 | $570.73 | $23.63 | x |
| 2019-03-31 | $641.60 | $23.63 | x |
| 2020-03-31 | $670.40 | $23.63 | x |
| 2021-03-31 | $655.03 | $23.63 | x |
| 2022-03-31 | $704.13 | $23.63 | x |
| 2023-03-31 | $753.60 | $23.63 | x |
| 2024-03-31 | $879.87 | $23.63 | x |
| 2025-03-31 | $855.56 | $23.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daiichi Sankyo Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.22%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.68%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 2.13x
- Recent ROE (18.22%) is above the historical average (6.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 6.96% | 7.26% | 0.64x | 1.50x | $-18.68 Billion |
| 2001 | 6.36% | 7.79% | 0.56x | 1.44x | $-24.35 Billion |
| 2002 | 5.95% | 7.07% | 0.60x | 1.40x | $-26.43 Billion |
| 2003 | 5.14% | 5.94% | 0.62x | 1.39x | $-32.03 Billion |
| 2004 | 6.36% | 7.28% | 0.64x | 1.36x | $-24.85 Billion |
| 2005 | 6.74% | 8.21% | 0.60x | 1.36x | $-23.38 Billion |
| 2006 | 7.09% | 9.47% | 0.58x | 1.29x | $-36.06 Billion |
| 2007 | 6.19% | 8.45% | 0.57x | 1.29x | $-48.32 Billion |
| 2008 | 7.85% | 11.10% | 0.59x | 1.20x | $-26.75 Billion |
| 2009 | -24.90% | -25.59% | 0.56x | 1.73x | $-302.04 Billion |
| 2010 | 4.87% | 4.40% | 0.64x | 1.73x | $-44.05 Billion |
| 2011 | 8.22% | 7.25% | 0.65x | 1.74x | $-15.13 Billion |
| 2012 | 1.26% | 1.11% | 0.60x | 1.88x | $-72.09 Billion |
| 2013 | 7.06% | 6.44% | 0.59x | 1.86x | $-26.64 Billion |
| 2014 | 6.22% | 6.78% | 0.48x | 1.89x | $-37.05 Billion |
| 2015 | 24.70% | 35.04% | 0.46x | 1.52x | $191.71 Billion |
| 2016 | 6.68% | 8.34% | 0.52x | 1.54x | $-40.86 Billion |
| 2017 | 4.55% | 5.60% | 0.50x | 1.63x | $-64.12 Billion |
| 2018 | 5.32% | 6.28% | 0.51x | 1.68x | $-53.02 Billion |
| 2019 | 7.47% | 10.05% | 0.45x | 1.67x | $-31.56 Billion |
| 2020 | 9.88% | 13.15% | 0.47x | 1.61x | $-1.51 Billion |
| 2021 | 5.97% | 7.89% | 0.46x | 1.64x | $-51.25 Billion |
| 2022 | 4.96% | 6.41% | 0.47x | 1.64x | $-68.12 Billion |
| 2023 | 7.55% | 8.54% | 0.51x | 1.74x | $-35.40 Billion |
| 2024 | 11.89% | 12.53% | 0.46x | 2.05x | $31.91 Billion |
| 2025 | 18.22% | 15.68% | 0.55x | 2.13x | $133.41 Billion |
Industry Comparison
This section compares Daiichi Sankyo Company Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $355,057,678,100
- Average return on equity (ROE) among peers: -0.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daiichi Sankyo Company Limited (DSKYF) | $1.71 Trillion | 6.96% | 1.23x | $37.02 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |